- ReShape Lifesciences' stock surged 20.63% in premarket trading.
- New U.S. patent granted for their diabetes neuromodulation technology.
- Analysts anticipate a significant upside potential of 129.52%.
ReShape Lifesciences (RSLS, Financial) experienced a notable 20.63% surge in premarket trading, reaching $0.3736. This spike followed the company's announcement of a notice of allowance for a U.S. patent on its innovative diabetes neuromodulation technology. The newly granted patent, designed to protect this breakthrough until 2037, leverages ReShape's vBlocâ„¢ technology to target Type 2 diabetes more effectively.
Analyst Forecast & Price Target
Wall Street analysts have weighed in on ReShape Lifesciences Inc (RSLS, Financial) with a one-year price target of $1.00, as determined by 1 analyst. This target encompasses both the high and low estimates, each set at $1.00. The anticipated return from this prediction represents an impressive upside potential of 129.52% from the current trading price of $0.44. For a more comprehensive look at the projections, visit the Reshape Lifesciences Inc (RSLS) Forecast page.
Brokerage Recommendations
The consensus recommendation from 1 brokerage firm places ReShape Lifesciences Inc (RSLS, Financial) at an average rating of 3.0, suggesting a "Hold" status. This recommendation is based on a scale where 1 indicates a Strong Buy and 5 suggests a Sell. Investors should consider this balanced advice while weighing potential investment opportunities.
